What is GEN inCode?
GEN inCode operates at the intersection of biotechnology and cardiology, specializing in genomic testing designed to prevent, diagnose, and treat cardiovascular disease. The company distinguishes itself through the integration of monogenic and polygenic risk assessments, which provide clinicians with a granular view of patient health profiles. Its flagship product suite, including CARDIO inCode-Score and LIPID inCode, is engineered to optimize patient treatment pathways by identifying risks before they manifest as acute clinical events. By transforming complex genetic data into actionable medical insights, GEN inCode addresses one of the most significant global health challenges, positioning itself as a critical player in the shift toward personalized, data-driven healthcare.
How much funding has GEN inCode raised?
GEN inCode has raised a total of $4.5M across 1 funding round:
Unspecified
$4.5M
Unspecified (2020): $4.5M with participation from Maven Capital Partners UK LLP
Key Investors in GEN inCode
Maven Capital Partners UK LLP
Maven Capital Partners UK LLP is a prominent venture capital and private equity firm that focuses on supporting high-growth companies through strategic financial backing and operational expertise.
What's next for GEN inCode?
Looking ahead, the strategic deployment of this capital will likely focus on expanding the commercial footprint of GEN inCode's diagnostic portfolio. As the company transitions into a more mature phase of enterprise-level growth, the focus will shift toward clinical validation studies and the integration of its risk assessment platforms into broader hospital networks. The firm is expected to prioritize the scaling of its laboratory operations and the expansion of its sales force to meet the rising demand for precision cardiovascular diagnostics. By maintaining its commitment to rigorous scientific standards, GEN inCode is poised to solidify its market position, potentially setting new benchmarks for how genomic data is utilized in the management of chronic cardiovascular conditions.
See full GEN inCode company page
